Trials / Completed
CompletedNCT06435676
A Study of Single and Multiple Doses HRS9531 Tablets in Healthy Subjects
A Phase I Study of the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of Single and Multiple Doses of HRS9531 Tablets in Healthy Subjects
- Status
- Completed
- Phase
- Phase 1
- Study type
- Interventional
- Enrollment
- 72 (actual)
- Sponsor
- Fujian Shengdi Pharmaceutical Co., Ltd. · Industry
- Sex
- Male
- Age
- 18 Years – 55 Years
- Healthy volunteers
- Accepted
Summary
The study is being conducted to evaluate the safety, tolerability, pharmacokinetics, and pharmacodynamics of single and multiple doses of HRS9531tablets in healthy subjects.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | HRS9531 | Single dose escalation of HRS9531 tablets in healthy subjects |
| DRUG | Placebo | Single dose of placebo in healthy adults |
| DRUG | HRS9531 | Multiple dose escalation of HRS9531 tablets in healthy subjects |
| DRUG | Placebo | Multiple dose of placebo in healthy adults |
Timeline
- Start date
- 2024-06-04
- Primary completion
- 2024-10-08
- Completion
- 2024-10-08
- First posted
- 2024-05-30
- Last updated
- 2025-05-22
Locations
1 site across 1 country: China
Source: ClinicalTrials.gov record NCT06435676. Inclusion in this directory is not an endorsement.